Find a Doctor

Physician Photo

David John Kuter, MD, DPhil

Director, Center for Hematology

My passion for hematology is based on my belief that scientific concepts can be usually applied at the bedside to provide patients with personalized, attentive care. But when science fails, a compassionate and soothing word may be equally helpful.

Departments
Hematology/Oncology
Department of Medicine

Specialties

  • Cancer Center
  • Hematology
Clinical Interests
Platelet Disorders
Thrombosis and hemostasis
Polycythemia vera
Thrombocytopenia
Essential thrombocytosis
Myeloproliferative diseases
Coagulation disorders
Anticoagulation
Anemia
Gaucher's disease
Chronic myeloid leukemia
Hemochromatosis
Hematology
Monoclonal gammopathy of unknown significance
Myelofibrosis
Locations
Boston: Massachusetts General Hospital
Medical Education
MD, Harvard Medical School
D.Phil., Oxford University
Residency, Massachusetts General Hospital
Fellowship, Massachusetts General Hospital
Board Certifications
Hematology, American Board of Internal Medicine
Internal Medicine, American Board of Internal Medicine
Medical Oncology, American Board of Internal Medicine
Gender
Male
Patient Age Group
Adult
Accepting New Patients
Accepting New Patients

BiographyDr. David Kuter is Director of Clinical Hematology at Massachusetts General Hospital and Professor of Medicine at Harvard Medical School. He received his undergraduate degree from Harvard College and his D. Phil. in Biochemistry while a Rhodes Scholar at Oxford University, before obtaining his medical degree from Harvard Medical School. Dr. Kuter divides his time between medical education of fellows and medical students, clinical care of patients with a wide range of hematological disorders, and clinical research of thrombopoietic agents. His basic science group was one of the labs that discovered thrombopoietin and his clinical research group carried out seminal studies using thrombopoietic agents in transfusion medicine and immune thrombocytopenia (ITP).  Dr Kuter is recipient of a number of awards, including the Irving London Teaching Award at Harvard Medical School, the Alfred Kranes Teaching Award at the Massachusetts General Hospital, the Douglas Family Foundation Prize for Research (2008 and 2010) at Massachusetts General Hospital, the Jane Green Memorial Prize for Teaching at the Massachusetts General Hospital, and the 2013 Earnest Beutler Award from the American Society of Hematology.  He has given over 500 invited lectures in over 50 countries and served as Visiting Professor in Beijing, Sydney, Tokyo, London, Durham, and New Haven.  Dr Kuter has authored or co-authored over 300 articles published in international peer-reviewed journals such as The Lancet, The New England Journal of Medicine and Blood.

ResearchCurrent areas of ongoing research:

  1. Hereditary hemorrhagic telangiectasis (HHT): NIH sponsored grant to assess effect of pamolidomide to reduce bleeding in patients with HHT.
  2. Immune thrombocytopenia (ITP): NIH sponsored grant to assess effect of addition of mycophenolyate to standard of care for patients with ITP.
  3. Heparin-induced thrombocytopepenia (HIT): lead in 17 center NIH-sponsored study of the natural history and treatment of HIT
  4. Polycythemia vera (P.vera): Incyte Corp study (Reveal Study) to assess the natural history, treatment and quality of life of patients with P. vera.
  5. ITP: Ph 1 study using anti-CD40 ligand antibody (BMS sponsor) to reduce the rate of thrombocytopenia in patients with ITP
  6. ITP: Ph 1 study assessing the use of Staph protein A (Protalix, Inc) in the treatment of ITP
  7. ITP: assessment of patients with ITP treated with TPO receptor agonists--effect on longterm remission
  8. ITP: assessment of TPO receptor agonists in raising the platelet count of thrombocytopenic patients about to have surgery
  9. ITP: study of platelet function in patients with ITP after treatment with romiplostim
  10. Autoimmune hemolytic anemia (AIHA): creator and major site for international registry for patients with this disorder.

PublicationsSelected peer-reviewed publications (of over 300)

  • Kuter DJ, Beeler D, Rosenberg RD. The purification and characterization of megapoietin: a megakaryocyte growth promoting protein. Proc Natl Acad Sci 1994;91:11104-11108.
  • Kuter DJ, et al. Thrombopoiesis and Thrombopoietins: Molecular, Cellular, Preclinical, and Clinical Biology. Humana Press, New York, 1997.
  • Murphy MJ, Kuter DJ, Eds. Thrombopoietin: From Molecule to Medicine. AlphaMed Press, Miamisburg, OH, 1998.
  • Bussel J, Kuter DJ, George J, McMillan R, Aledort LM, Conklin GT, Lichtin AE, Lyons RM, Nieva J,Wasser J, Wiznitzer I, Kelly R, Chen CF, Nichol J. AMG 531, a thrombopoiesis-stimulating protein, for ITP. New Engl J Med 2006;355:1672-1681.
  • Kuter DJ, et al. Randomized, controlled, 6-month evaluation of AMG531 in patients with chronic immune thrombocytopenic purpura. Lancet 2008;371:395-403.
  • Kuter DJ et al. Romiplostim or standard of care in patients with immune thrombocytopenia. NEJM 2010;363:1889-1899.

Romiplostim more effective than standard care for immune thrombocytopenia

A new study finds that an FDA-approved drug to treat the rare autoimmune disorder immune thromobocytopenia (ITP) is more effective than earlier medical therapies in helping patients avoid surgical treatment and significantly improving their quality of life.

Hematology/Oncology
55 Fruit Street
Yawkey 7B
Boston, MA 02114-2696

Phone: 617-724-4000
Phone 2: 617-726-8033
Fax: 617-724-6801

Hematology/Oncology
55 Fruit Street
Yawkey 7B
Boston, MA 02114-2696

Phone: 617-724-4000
Phone 2: 617-726-8033
Fax: 617-724-6801

Request a new patient appointment

Call the Massachusetts General Hospital physician referral service at 800-711-4644.

Insurance plans - what you need to know

Mass General accepts most health insurance plans. Find out what you need to know before coming to Mass General.

Directions to Mass General

Driving to Mass General? Get driving directions or locate a parking lot on the hospital's main campus.